COR

Business Context and Reporting Period

This Form 10-Q covers AmerisourceBergen Corporation (now Cencora, Inc.) for the quarterly period ended June 30, 2007. The Company is a pharmaceutical services provider operating primarily in the United States and Canada, organized into two reportable segments: Pharmaceutical Distribution (comprising AmerisourceBergen Drug Corporation, Specialty Group, and Packaging Group) and PharMerica (Long-Term Care and workers' compensation services). Notably, the Company completed the spin-off of its PharMerica Long-Term Care business into a new independent entity, PharMerica Corporation, on July 31, 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Operating revenue increased 7% for the quarter and 10% for the nine-month period compared to the prior year. Growth was driven by the Pharmaceutical Distribution segment, particularly the Specialty Group (30% growth YTD), offset by a decision not to renew a contract with a large, low-margin customer.
• Profitability: Net income rose 9% for the quarter and 10% for the nine-month period. Operating income increased 11% (quarter) and 16% (YTD).
• Antitrust Gains: The Company recognized significant gains from antitrust litigation settlements ($31.9 million in the quarter; $35.6 million YTD), which were recorded as reductions to cost of goods sold and materially boosted gross profit and operating income.
• PharMerica Performance: The PharMerica segment saw operating income decline 56% for the quarter and 25% YTD, primarily due to increased bad debt expenses in the Long-Term Care business and higher operating costs in the PMSI business.
• Share Repurchases: The Company aggressively reduced share count, purchasing 18.4 million shares for $888.4 million during the nine months ended June 30, 2007.

Guidance, Outlook, and Risks

• Revenue Outlook: Management expects operating revenue growth to moderate in the fourth quarter, projecting full-year fiscal 2007 growth between 9% and 10%.
• Cash Flow Guidance: The Company raised its full-year operating cash flow expectation to between $850 million and $950 million, anticipating a working capital increase in the fourth quarter.
• Acquisition Status (Bellco): The planned $235 million acquisition of Bellco Health is pending. The deal faces uncertainty due to a Drug Enforcement Administration (DEA) suspension of Bellco's license to distribute controlled substances, which was settled in June 2007. Closing is expected by September 30, 2007, subject to agreement on revised terms.
• Regulatory Risks:
  • Anemia Drugs: Sales of anemia drugs (approx. 6% of revenue) are declining due to FDA warning label requirements and CMS reimbursement restrictions. Future growth may be impacted by further dosage limits or reimbursement cuts.
  • DEA Enforcement: The Company's Orlando distribution center license was suspended in April 2007 due to diversion concerns. A settlement was reached, with license reinstatement expected in August 2007, though future enforcement actions remain a risk.
  • Reimbursement Changes: Ongoing changes in Medicare Part D and Medicaid reimbursement methodologies pose risks to margins, particularly in the Long-Term Care and Specialty segments.

Investor Verification Checklist

• Bellco Acquisition: Verify the final terms and closing status of the Bellco Health acquisition given the DEA regulatory hurdles.
• Anemia Drug Exposure: Assess the long-term impact of CMS and FDA restrictions on anemia drug sales on future revenue growth.
• PharMerica Spin-off: Confirm the financial restatement of historical results to reflect PharMerica Long-Term Care as a discontinued operation in future filings.
• Antitrust Settlements: Evaluate the sustainability of earnings given the significant contribution of one-time antitrust litigation gains to gross profit.
• Working Capital Trends: Monitor the increase in days sales outstanding (DSO) in the Specialty Group and PharMerica segments, which may pressure future cash flows.